Close Menu

This story has been updated from a previous version to include comments made by NantHealth executives during the company's earnings call.

NEW YORK – NantHealth reported after the close of the market Thursday that its revenue rose 6 percent during the 2019 first quarter to $23.7 million from $22.3 million in the same period in 2018.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Hastings Center's Erik Parens argues in a Scientific American opinion piece that the current pandemic underscores the need to reconsider the hope placed in genomic medicine. 

The Los Angeles Times writes that Operation Warp Speed has an ambitious timeline for developing a COVID-19 vaccine.

The Sydney Morning Herald reports that Australia is launching its trial of preconception carrier testing Tuesday.

In PNAS this week: autosomal genes commonly affected by loss-of-function variants, variants implicated in testis development disorders, and more.